Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30779
Summary. The purpose of the study was to investigate the specifics of the clinical and morphological course of prostate cancer (PCa) in patients with metabolic syndrome (MS) and its influence on the spread of the metastatic process. Materials and methods. The study included 79 patients with locally advanced PCa who underwent inpatient treatment in the period from 2015 to 2020 in plastic and reconstructive department of National cancer institute of Ukraine and undergo further outpatient observation, diagnosis and treatment during the time before the development of bone metastasis (BM) from the moment of radical prostatectomy (RP), among which MS was diagnosed in 40 (50.6%) and absent in 39 (49.4%). The average age of the patients was: 69 (59–80) years. Patients participated in the study with existing MS were divided into 2 studied groups: 17 (21.5%) with moderate risk (Grade group 2, 3) and 23 (29.1%) with high risk (Grade group 4, 5) of disease progression, in contrast to patients without MS: 20 (25.3%) with Grade group 2, 3 and 19 (24.1%) with Grade group 4, 5. The average initial level of total PSA in patients with MS and Grade group 2, 3 was: 16.35 ng/ml, Grade group 4, 5 — 23.75 ng/ml. In patients without MS with Grade group 2, 3 — 14 ng/ml, Grade group 4, 5 — 21.45 ng/ml. Results. Among 79 study participants, after RP, 35 (44.3%) were diagnosed with the development of bone and visceral metastases, in contrast to 44 (55.7%) without metastases. Among 35 patients with the development of BM — 27 (77.1%) with MS, 8 (22.9%) — no signs of MS. BM was combined with visceral metastases in 17 (48.5%) patients, MS was found in most cases of this cohort of 11 (64.7%) patients. BM in the subgroup of moderate risk (Gleason
{"title":"Особливості впливу метаболічного синдрому на агресивність перебігу раку передміхурової залози","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30779","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30779","url":null,"abstract":"Summary. The purpose of the study was to investigate the specifics of the clinical and morphological course of prostate cancer (PCa) in patients with metabolic syndrome (MS) and its influence on the spread of the metastatic process. Materials and methods. The study included 79 patients with locally advanced PCa who underwent inpatient treatment in the period from 2015 to 2020 in plastic and reconstructive department of National cancer institute of Ukraine and undergo further outpatient observation, diagnosis and treatment during the time before the development of bone metastasis (BM) from the moment of radical prostatectomy (RP), among which MS was diagnosed in 40 (50.6%) and absent in 39 (49.4%). The average age of the patients was: 69 (59–80) years. Patients participated in the study with existing MS were divided into 2 studied groups: 17 (21.5%) with moderate risk (Grade group 2, 3) and 23 (29.1%) with high risk (Grade group 4, 5) of disease progression, in contrast to patients without MS: 20 (25.3%) with Grade group 2, 3 and 19 (24.1%) with Grade group 4, 5. The average initial level of total PSA in patients with MS and Grade group 2, 3 was: 16.35 ng/ml, Grade group 4, 5 — 23.75 ng/ml. In patients without MS with Grade group 2, 3 — 14 ng/ml, Grade group 4, 5 — 21.45 ng/ml. Results. Among 79 study participants, after RP, 35 (44.3%) were diagnosed with the development of bone and visceral metastases, in contrast to 44 (55.7%) without metastases. Among 35 patients with the development of BM — 27 (77.1%) with MS, 8 (22.9%) — no signs of MS. BM was combined with visceral metastases in 17 (48.5%) patients, MS was found in most cases of this cohort of 11 (64.7%) patients. BM in the subgroup of moderate risk (Gleason","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30634
early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study
{"title":"Особливості перебігу раку грудної залози з низьким рівнем експресії HER2/neu","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30634","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30634","url":null,"abstract":"early disease stages. It was determined that the frequency of BC recurrences was higher in patients with greater HER2 expression, but it was not statistically significant, p >0.05. Conclusions. The obtained results propose general concepts of HER2-low BC and require further study","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"64 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30530
{"title":"Вибір ад’ювантного лікування раку ендометрія ІІІА–С стадій","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30530","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30530","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"369 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30652
{"title":"Формування радіойодорезистентності у хворих на диференційований рак щитоподібної залози та можливості її прогнозування. Використані дані літератури та власних досліджень","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30652","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30652","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"82 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208495","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30589
{"title":"Клінічна характеристика, особливості лікування та досягнення кінцевих точок, оцінені в реальній клінічній практиці застосування талазопарібу у пацієнтів із HER2-негативним BRCA-асоційованим раком грудної залози","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30589","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30589","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208712","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30766
{"title":"Найвагоміші досягнення наукових досліджень державного некомерційного підприємства «Національний інститут раку» у 2022р.","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30766","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30766","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30486
{"title":"Метастази раку в лімфатичні вузли шиї без встановленого первинного вогнища","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30486","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30486","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207052","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30797
pertinent issues is the diagnosis and treatment of T-cell skin lymphomas using a diagnostic panel of a wide range of modern examination methods (histological, immunological, molecular-genetic), which allow the correct determination of prognosis and optimization of therapy using individualized treatment approaches with the newest methods
{"title":"Первинні Т-клітинні лімфоми шкіри: класифікація, діагностика, лікування (огляд літератури)","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30797","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30797","url":null,"abstract":"pertinent issues is the diagnosis and treatment of T-cell skin lymphomas using a diagnostic panel of a wide range of modern examination methods (histological, immunological, molecular-genetic), which allow the correct determination of prognosis and optimization of therapy using individualized treatment approaches with the newest methods","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"17 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136207051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.32471/clinicaloncology.2663-466x.50-2.30837
{"title":"Особливості хірургічного етапу лікування раку грудної залози за наявності згрупованих мікрокальцифікатів","authors":"","doi":"10.32471/clinicaloncology.2663-466x.50-2.30837","DOIUrl":"https://doi.org/10.32471/clinicaloncology.2663-466x.50-2.30837","url":null,"abstract":"","PeriodicalId":487505,"journal":{"name":"Клиническая онкология","volume":"7 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136208502","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：